文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19药物治疗:动态系统评价与网状Meta分析

Drug treatments for covid-19: living systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2020-07-30
一句话结论在重症COVID-19患者中,全身性糖皮质激素、白介素-6受体拮抗剂(与糖皮质激素联用)和Janus激酶抑制剂可能降低死亡率;在非重症患者中,奈玛特韦/利托那韦和莫努匹韦可能减少住院。

本动态系统评价与网状Meta分析纳入463项随机临床试验、共166 581例疑似、可能或确诊COVID-19患者,比较药物与标准治疗或安慰剂的效果。与标准治疗相比,在多为重症的患者中,全身性糖皮质激素(每1000例减少23例死亡,95%可信区间减少40至7例,中等确定性)、白介素-6受体拮抗剂与糖皮质激素联用(每1000例减少23例,减少36至7例,中等确定性)和Janus激酶抑制剂(每1000例减少44例,减少64至20例,高确定性)降低死亡率。在非重症患者中,奈玛特韦/利托那韦(每1000例减少36例住院,减少41至26例,中等确定性)和莫努匹韦(每1000例减少19例,减少29至5例,中等确定性)可能减少住院;瑞德西韦可能减少住院(每1000例减少29例,减少40至6例,低确定性)。仅莫努匹韦有至少中等质量证据显示缩短症状缓解时间(缩短3.3天,缩短4.8至1.6天,中等确定性);羟氯喹可能增加机械通气风险(中等确定性)。

要点

  • 重症COVID-19患者中,Janus激酶抑制剂降低死亡率(每1000例减少44例,95%可信区间减少64至20例,高确定性)。
  • 重症COVID-19患者中,全身性糖皮质激素降低死亡率(每1000例减少23例,95%可信区间减少40至7例,中等确定性)。
  • 重症COVID-19患者中,白介素-6受体拮抗剂与糖皮质激素联用降低死亡率(每1000例减少23例,95%可信区间减少36至7例,中等确定性)。
  • 非重症COVID-19患者中,奈玛特韦/利托那韦减少住院(每1000例减少36例,95%可信区间减少41至26例,中等确定性),莫努匹韦减少住院(每1000例减少19例,95%可信区间减少29至5例,中等确定性)。
  • 羟氯喹可能增加机械通气风险(中等确定性)。

适用人群与场景

  • 疑似、可能或确诊COVID-19的随机临床试验受试者。
  • 死亡结局证据主要来自重症患者;住院结局证据来自非重症患者。

研究设计与关键结果

  • 研究类型:动态系统评价与网状Meta分析;纳入463项随机临床试验,共166 581例患者;267项试验(57.7%)和89 814例患者(53.9%)为本次更新新增;265项试验(57.2%)评估的治疗组至少100例患者或20个事件,达到纳入分析阈值。
  • 与标准治疗相比,在多为重症的患者中:全身性糖皮质激素降低死亡率(每1000例减少23例死亡,95%可信区间减少40至7例,中等确定性);白介素-6受体拮抗剂与糖皮质激素联用时降低死亡率(每1000例减少23例,95%可信区间减少36至7例,中等确定性);Janus激酶抑制剂降低死亡率(每1000例减少44例,95%可信区间减少64至20例,高确定性)。
  • 与标准治疗相比,在非重症患者中:奈玛特韦/利托那韦可能减少住院(每1000例减少36例,95%可信区间减少41至26例,中等确定性);莫努匹韦可能减少住院(每1000例减少19例,95%可信区间减少29至5例,中等确定性);瑞德西韦可能减少住院(每1000例减少29例,95%可信区间减少40至6例,低确定性)。
  • 仅莫努匹韦有至少中等质量证据显示缩短症状缓解时间(缩短3.3天,95%可信区间缩短4.8至1.6天,中等确定性);其他几种药物显示可能获益。
  • 几种药物可能增加导致停药的不良反应风险;羟氯喹可能增加机械通气风险(中等确定性)。

证据类型、等级与局限

  • 证据类型:动态系统评价与网状Meta分析,采用GRADE方法评估证据确定性。
  • 偏倚风险评估使用修改版Cochrane偏倚风险2.0工具。
  • GRADE确定性分级:Janus激酶抑制剂降低死亡率为高确定性;全身性糖皮质激素、白介素-6受体拮抗剂联合糖皮质激素降低死亡率,奈玛特韦/利托那韦和莫努匹韦减少住院,莫努匹韦缩短症状缓解时间,羟氯喹增加机械通气风险均为中等确定性;瑞德西韦减少住院为低确定性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 重症COVID-19患者中,全身性糖皮质激素、白介素-6受体拮抗剂(与糖皮质激素联用)和Janus激酶抑制剂可能降低死亡率并带来其他重要获益。
  • 非重症COVID-19患者中,莫努匹韦和奈玛特韦/利托那韦可能减少住院。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare the effects of treatments for coronavirus disease 2019 (covid-19).

DESIGN: Living systematic review and network meta-analysis.

DATA SOURCES: WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature, up to 3 December 2021 and six additional Chinese databases up to 20 February 2021. Studies identified as of 1 December 2021 were included in the analysis.

STUDY SELECTION: Randomised clinical trials in which people with suspected, probable, or confirmed covid-19 were randomised to drug treatment or to standard care or placebo. Pairs of reviewers independently screened potentially eligible articles.

METHODS: After duplicate data abstraction, a bayesian network meta-analysis was conducted. Risk of bias of the included studies was assessed using a modification of the Cochrane risk of bias 2.0 tool, and the certainty of the evidence using the grading of recommendations assessment, development, and evaluation (GRADE) approach. For each outcome, interventions were classified in groups from the most to the least beneficial or harmful following GRADE guidance.

RESULTS: 463 trials enrolling 166 581 patients were included; 267 (57.7%) trials and 89 814 (53.9%) patients are new from the previous iteration; 265 (57.2%) trials evaluating treatments with at least 100 patients or 20 events met the threshold for inclusion in the analyses. Compared with standard care, three drugs reduced mortality in patients with mostly severe disease with at least moderate certainty: systemic corticosteroids (risk difference 23 fewer per 1000 patients, 95% credible interval 40 fewer to 7 fewer, moderate certainty), interleukin-6 receptor antagonists when given with corticosteroids (23 fewer per 1000, 36 fewer to 7 fewer, moderate certainty), and Janus kinase inhibitors (44 fewer per 1000, 64 fewer to 20 fewer, high certainty). Compared with standard care, two drugs probably reduce hospital admission in patients with non-severe disease: nirmatrelvir/ritonavir (36 fewer per 1000, 41 fewer to 26 fewer, moderate certainty) and molnupiravir (19 fewer per 1000, 29 fewer to 5 fewer, moderate certainty). Remdesivir may reduce hospital admission (29 fewer per 1000, 40 fewer to 6 fewer, low certainty). Only molnupiravir had at least moderate quality evidence of a reduction in time to symptom resolution (3.3 days fewer, 4.8 fewer to 1.6 fewer, moderate certainty); several others showed a possible benefit. Several drugs may increase the risk of adverse effects leading to drug discontinuation; hydroxychloroquine probably increases the risk of mechanical ventilation (moderate certainty).

CONCLUSION: Corticosteroids, interleukin-6 receptor antagonists, and Janus kinase inhibitors probably reduce mortality and confer other important benefits in patients with severe covid-19. Molnupiravir and nirmatrelvir/ritonavir probably reduce admission to hospital in patients with non-severe covid-19.

SYSTEMATIC REVIEW REGISTRATION: This review was not registered. The protocol is publicly available in the supplementary material.

READERS' NOTE: This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication. This is the fifth version of the original article published on 30 July 2020 (BMJ 2020;370:m2980), and previous versions can be found as data supplements. When citing this paper please consider adding the version number and date of access for clarity.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Siemieniuk RA, Bartoszko JJ, Zeraatkar D, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020. PMID: 32732190. doi:10.1136/bmj.m2980

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。